Literature DB >> 24860863

Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.

Jonathan Silver.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 24860863     DOI: 10.1001/jama.2014.6672

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Multi-modal management of acromegaly: a value perspective.

Authors:  Kristopher T Kimmell; Robert J Weil; Nicholas F Marko
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

2.  Ziv-aflibercept in macular disease.

Authors:  Ahmad M Mansour; Sara I Al-Ghadban; Muhammad H Yunis; Marwan E El-Sabban
Journal:  Br J Ophthalmol       Date:  2015-02-12       Impact factor: 4.638

3.  Human IgG1 antibodies suppress angiogenesis in a target-independent manner.

Authors:  Sasha Bogdanovich; Younghee Kim; Takeshi Mizutani; Reo Yasuma; Laura Tudisco; Valeria Cicatiello; Ana Bastos-Carvalho; Nagaraj Kerur; Yoshio Hirano; Judit Z Baffi; Valeria Tarallo; Shengjian Li; Tetsuhiro Yasuma; Parthasarathy Arpitha; Benjamin J Fowler; Charles B Wright; Ivana Apicella; Adelaide Greco; Arturo Brunetti; Menotti Ruvo; Annamaria Sandomenico; Miho Nozaki; Ryo Ijima; Hiroki Kaneko; Yuichiro Ogura; Hiroko Terasaki; Balamurali K Ambati; Jeanette Hw Leusen; Wallace Y Langdon; Michael R Clark; Kathryn L Armour; Pierre Bruhns; J Sjef Verbeek; Bradley D Gelfand; Sandro De Falco; Jayakrishna Ambati
Journal:  Signal Transduct Target Ther       Date:  2016-01-28

Review 4.  Pharmacological agents in development for diabetic macular edema.

Authors:  Mohammad Ali Sadiq; Muhammad Sohail Halim; Muhammad Hassan; Neil Onghanseng; Irmak Karaca; Aniruddha Agarwal; Rubbia Afridi; Yasir J Sepah; Diana V Do; Quan Dong Nguyen
Journal:  Int J Retina Vitreous       Date:  2020-07-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.